Junye Wang

机构：Sun Yat-sen University, Wuhan University, Sun Yat-sen University Cancer Center, Affiliated Hospital of Jining Medical University, Jining Medical University · ORCID：0000-0001-7968-7121

发表论文 63 篇 · 总被引 1629 次 · h-index 19

代表论文

• Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial (2022 · Cancer Cell · 被引 578)
• Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2) (2022 · Nature Communications · 被引 151)
• Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers (2024 · Drug Resistance Updates · 被引 115)
• Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial (2025 · The Lancet Oncology · 被引 61)
• SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC). (2024 · Journal of Clinical Oncology · 被引 31)
• Pan-Immune-Inflammatory Value in Patients with Non-Small-Cell Lung Cancer Undergoing Neoadjuvant Immunochemotherapy (2023 · Journal of Inflammation Research · 被引 28)